DNL343 is a novel investigational ALS therapy that targets eIF2B, a central regulator of the integrated stress response (ISR).
The Sean M. Healey International Prize for Innovation in ALS Research recognizes an individual or a team of investigators who catalyze exceptional discoveries leading to a transformative advance in therapy development in ALS.
The Sean. M. Healey & AMG Center for ALS at Massachusetts General Hospital is accepting nominations for the 2022 Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing in acknowledgement of the important scientific work being done in ALS.
One way people with ALS can help move ALS research forward is by choosing to donate their bodies at the time of death to ALS research.
The Gupta Family Endowed Prize for Innovation in ALS Care is an annual global prize to honor ground-breaking new approaches that lead to exceptional care for individuals living with amyotrophic lateral sclerosis (ALS).
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in conjunction with Seelos Therapeutics and NINDS have announced the first patient-dosing in the NINDS-funded Expanded Access Protocol (EAP) for Trehalose.
The HEALEY ALS Platform Trial is designed to evaluate multiple investigational products simultaneously, thus accelerating the development of effective and breakthrough treatments for people living with ALS.
Results in cells and mice demonstrate that gene therapy using antisense oligonucleotides can restore stathmin-2 protein loss, a hallmark of TDP-43–dependent neurodegeneration.
The HEALEY ALS Platform Trial completes enrollment for Regimen E evaluating SLS-005 (Trehalose) by Seelos Therapeutics. The HEALEY ALS Platform Trial completes enrollment for Regimen E evaluating SLS-005 (Trehalose) by Seelos Therapeutics. BOSTON –
The HEALEY ALS Platform Trial is adding a new investigational drug, DNL343, to continue to research new treatments for ALS (Amyotrophic Lateral Sclerosis or Lou Gehrig’s disease).
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.
